Lipocine Inc.
Organization details
- Legal name
- Lipocine Inc.
- Former names
- Marathon BAR Corp
- Ownership
- Public
- Status
- Active
- Sector (GICS)
- Health Care
- SIC code
- 2834 — Pharmaceutical Preparations
- Jurisdiction of incorporation
- Delaware
- Headquarters city
- Salt Lake City
- Headquarters country
- United States
- Fiscal year end
- December
- Ticker symbol
- LPCN
- Primary stock exchange
- Nasdaq
Identifiers
- SEC CIK
- 0001535955
- EIN
- 99-0370688
Board of directors
-
Jeffrey Arvin Fink · DirectorSince 2023
-
Jill M. Jene · DirectorSince 2023
-
John W. Higuchi · DirectorSince 2023
-
Mahesh Patel V · Director · Chief Executive OfficerSince 2023
-
Michael Grissinger · DirectorSince 2026
-
Richard Dana Ono · DirectorSince 2023
-
Spyros Papapetropoulos · DirectorSince 2023
Chief executives
Director election results
Annual meeting of June 3, 2026. Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.
-
86.6%
-
87.5%
-
89.2%
-
89.5%
Board connections
2 of this board's directors also sit on 4 other boards. 4 are in the same sector.
-
Adicet Bio Inc. Same sectorvia Michael Grissinger
-
Akari Therapeutics plc Same sectorvia Michael Grissinger
-
Aprea Therapeutics Inc. Same sectorvia Michael Grissinger
-
Neuphoria Therapeutics Inc. Same sectorvia Spyros Papapetropoulos
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
- Bought, last 12 months
- $516,774
- 7 purchases by 2 insiders
- Sold, last 12 months
- $0
- 0 sales by 0 insiders
| Date | Insider | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Sep 30, 2026 | John W. Higuchi Director | Open-market purchase | +15,970 | $2.23 | $35,613 |
| Sep 29, 2026 | John W. Higuchi Director | Open-market purchase | +9,037 | $2.15 | $19,430 |
| Sep 28, 2026 | John W. Higuchi Director | Open-market purchase | +12,561 | $2.16 | $27,132 |
| Apr 7, 2026 | John W. Higuchi Director | Open-market purchase | +40,000 | $2.03 | $81,200 |
| Apr 6, 2026 | John W. Higuchi Director | Open-market purchase | +123,000 | $2.05 | $252,150 |
| Apr 6, 2026 | Mahesh Patel V Director, Officer (Chief Executive Officer) | Open-market purchase | +25,000 | $2.03 | $50,750 |
| Apr 2, 2026 | Mahesh Patel V Director, Officer (Chief Executive Officer) | Open-market purchase | +25,000 | $2.02 | $50,500 |
| Mar 8, 2024 | Mahesh Patel V Director, Officer (CEO and President) | Grant or award | +4,893 | — | — |
| Mar 8, 2024 | Fogarty Krista Officer (Principal Accounting Officer) | Grant or award | +991 | — | — |
| May 25, 2023 | Mahesh Patel V Director, Officer (CEO and President) | Open-market purchase | +8,706 | $5.03 | $43,791 |
| Mar 24, 2023 | Mahesh Patel V Director, Officer (CEO and President) | Open-market purchase | +150,000 | $0.32 | $48,000 |
| Mar 20, 2023 | Richard Dana Ono Director | Open-market purchase | +4,000 | $0.34 | $1,360 |
| Mar 17, 2023 | Mahesh Patel V Director, Officer (CEO and President) | Open-market purchase | +50,000 | $0.33 | $16,500 |
Peers
Compare boardsOrganizations in the same sector, closest in location and size first.
Questions about Lipocine Inc.
Who is the CEO of Lipocine Inc.?
Mahesh Patel V is Lipocine Inc.'s CEO and President.
How many directors are on Lipocine Inc.'s board?
Lipocine Inc.'s board has 7 directors: Jeffrey Arvin Fink, Jill M. Jene, John W. Higuchi, Mahesh Patel V, Michael Grissinger, Richard Dana Ono and Spyros Papapetropoulos.
Are Lipocine Inc. insiders buying or selling shares?
Over the last 12 months, Lipocine Inc. insiders bought $516,774 of shares in 7 purchases and made no open-market sales on the open market, as reported to the SEC on Forms 4 and 5.
Embed this board on your site
Paste this where the board should appear. It always shows the current directors and links back here.
<div data-bod-board="lipocine-inc"></div>
<script src="https://boardofdirectors.review/embed.js" async></script>Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.